AMORPHOUSTRISODIUM SACUBITRIL VALSARTANAND PROCESS FOR ITS PREPARATION
Related Application:
This application claims the benefit of priority of our Indian patent applications IN
201641037145 filed on October 28, 2016, IN 201641038689 filed on November 11, 2016
and IN 201641043910 filed on December 22, 2016 which are incorporated herein by
reference.
TECHNICAL FIELD
The present invention relates to methods for preparation of amorphous form of Sacubitril Val saltan Tri sodium complex represented by the structural Formula-I and processes for the preparation thereof.
The present invention also relates to novel crystalline forms of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt [Sacubitril sodium] represented by the structural Formula-Hand processes for the preparation thereof.

The present invention also relates to novel crystalline forms of (S)-N-(5 1 -Carboxy-2-Methyl- Prop-1 -yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt [Valsartan disodium] represented by the structural Formula-I and processes for the preparation thereof.
BACKGROUND AND PRIOR ART OF THE DISCLOSURE ENTRESTO-^ is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and 10 hospitalization for heart failure in patients with chronic heart failure (NY HA Class II-IV) and reduced ejection fraction.

Sacubitril sodium is disclosed in US 5217996A along with methodsfor preparation of Sacubitril sodium.
Journal of Medicinal Chemistry, 1995, 38 (10), pp 1689"1700 discloses the process for preparation of Sacubitril sodium
CN105503638A discloses process of preparation of Sacubitril sodium using ethanol and tetrahydrofuran (1:1) mixed solvent
CN105693543 discloses various salts of Sacubitril like Sacubitril potassium, magnesium Sacubitril, Sacubitril t-butyl amine salt, Sacubitril ethanol amine salt, Sacubitril piperazine, Sacubitril calcium salt, Sacubitril tromethaminesalt, Sacubitril tri ethanol amine salt This patent application also discloses Sacubitril magnesium amorphous of X- ray powder diffraction pattern.
CN105837464A discloses various crystal line forms of Sacubitril sodium such as FormA, Form B, Form C and Form D along with amorphous form
This Chinese patent application disci oses Sacubitril sodium of crystalline FormA which is characterized by X- ray powder diffraction pattern (using Cu-K radiation) the characteristic diffraction peaks corresponding 2: values are 6.0 e 0.2 £ 6.6 e 0.2 £ 9.0 e 0.2 e, 12.2 e 0.2 e, 13.2 e 0.2 e, 15.1 e 0.2 e, 17.1 e 0.2 e, 17.8 e 0.2 e, 18.3 e 0.2 e, 19.2 e 0.2 e; 19.7 e 0.2 e, 20.2 e 0.2 e, 20.8 e 0.2 e, 21.4 e 0.2 e, 21.6 e 0.2 e, 22.6 e 0.2 e, 26.7 e 0.2 e
This Chinese patent application discloses Sacubitril sodium of crystal line Form B which is characterized by X- ray powder diffraction pattern (using Cu-K radiation) the characteristic diffraction peaks corresponding 2: values are 6.1 e 0.2 £ 7.1 e 0.2 £ 7.7 e 0.2 e; 11.8 e 0.2 £ 12.3 e 0.2 £ 12.6 e 0.2 £ 13.6 e 0.2 £ 15.4 e 0.2 £ 16.4 e 0.2 £ 19.9 e 0.2 e\ 20.1 e 0.2 e, 23.7 e 0.2 e\ 24.0 e 0.2 e\ 24.8 e 0.2 e\ 25.9 e 0.2 e\ 26.2 e 0.2 e This Chinese patent application discloses Sacubitril sodium of crystalline Form C which is characterized by X- ray powder diffraction pattern (using Cu-K radiation) the characteristic diffraction peaks corresponding 2: values are 6.3 e 0.2 £ 7.3 e 0.2 £ 12.7e 0.2 e\ 14.7 e 0.2 e, 15.9 e 0.2 e, 18.5 e 0.2 e; 19.2 e 0.2 e\ 22.4 e 0.2 e, 22.7 e 0.2 e, 23.6 e 0.2 e\ 27.0 e 0.2 e

This Chinese patent application discloses Sacubitril sodium of crystalline Form D which is characterized by X- ray powder diffraction pattern (using Cu-K radiation) the characteristic diffraction peaks corresponding 2: values are value 6.3 e 0.2 e; 7.3 e 0.2 £ 12.0 e 0.2 £ 12.8 e 0.2 e\ 16.6 e 0.2 e\ 17.0 e 0.2 £ 18.5 e 0.2 £ 20.0 e 0.2 e\ 21.7 e 0.2 e\ 22.5 e 0.2 e, 23.9 e 0.2 e\ 26.3 e 0.2 e\ 27.1 e 0.2 e
PCT Publication No. W02016074651A1 discloses various crystalline Sacubitril amine salts. This PCT publication discloses the crystalline salt of Sacubitril with cycl ohexy I ami ne, the characteri sti c diff racti on peaks correspondi ng 2: val ues are 7.4,15.0, 18.0, 19.9, 21.6 (ee 0.2e2:), the crystalline salt of Sacubitril with isopropyl amine, the characteristic diffraction peaks correspondi ng 2: val ues are 3.1, 9.5, 12.6, 18.5, 24.6 (ee 0.2e 2:), the crystalline salt of Sacubitril with isopropyl amine, the characteristic diffraction peaks corresponding 2 :values are 8.0, 9.8,16.1,17.8, 20.2 (ee 0.2e2:).
PCT Publication No. W 02016074651A1 discloses various crystal line and semi crystal line forms of Sacubitril calcium salt This PCT discloses the crystalline form I of crystalline Sacubitril calcium salt with characteristic diffraction peaks corresponding 2::values are 3.6, 6.4, 8.4,10.8,14.5,17.7, 20.6 and 22.5 (ee 0.2e2:).This PCT discloses the crystalline form II of crystalline Sacubitril calcium salt with characteristic diffraction peaks corresponding 2: values are 3.2, 7.4, 11.4, 12.9, 16.2, 18.7, 22.5, 23.7 and 27.1(ee 0.2e 2:).
This PCT discloses the semi crystal line form III of the calcium salt of Sacubitril with characteristic diffraction peaks corresponding 2: values are 4.0 and 4.7 e 0.2e This PCT discloses the semi crystal line form IV of the calcium salt of Sacubitril with characteristic diffraction peaks corresponding 2::values are 4.6; 6.4 and 14.3 e 0.2e. This PCT publication also discloses the comparative stability study of crystalline Sacubitril calcium salt and crystal I i ne Sacubitril sodium salt T his study shows a sample of the calci um salt of Sacubitril (form I) upon exposing to the temperature of 80eC at0% relative humidity (RH) and 75% R H f or 3 days. T he crystal I i ne state of the cal ci um salt of Sacubitri I di d not change during this time period. The same experiment was also conducted with the sodium salt of

Sacubitril, which exhibited a high rate of polymorph instability and at 75% RH the sample became completely amorphous (see Table 1).
T hus there is a need to devel op stable crystal I i ne polymorphs of Sacubitri I sodi um, with the process involving be simple and cost-effective.
PCT Publication No. WO 2007056546 A1 discloses crystalline Valsartan disodium salt, but does not disclose any analytical data or process for preparation of the same;
PCT Publication No. WO 200206253 A1 discloses amorphous and crystalline Valsartan disodium salt; Example 5 of the publication discloses a process for the preparation of the Valsartan disodium salt involving dissolving the valsartan in ethanol, mixing with 2 N sodium hydroxide solution and concentrating by evaporation, and the residue is evaporated with each of ethanol and ethyl acetate. The white residue is stirred in hot acetonitrile and f i I tered by sucti on at room temperature. Drying in a high vacuum at 80eC, overni ght y i el ds (S)-N-(1- carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1Htetrazol-5-yl)-biphenyl-4-ylmethyl]- amine disodium salt as a white powder. Melting point from 260eC, brownish discolouration at 295eC. There is no reference provided for the nature of the product whether it is amorphous or crystalline.
Example 11 of the same PCT publication No. WO 200206253 discloses a process for the preparation of the Hydrate of valsartan disodium salt (2.4 e 1.0 mole H20). A solution was valsartan in isopropanol was added 2N sodium hydroxide solution dropwise at ca. 25eC. The clear solution (pH 7.2) was concentrated under vacuum at ca.40eC. The amorphous residue of the disodium salt was suspended in 100 ml of isopropanol, and water was

removed by concentrating under vacuum once more at ca. 40eC and degassing. The amorphous residue was suspended in 75 ml of acetone and 2 ml of water at ca. 40eC. At ca. 25-30eC, 200 ml of tert-butyl methyl ether were added, whereby constituents that were initially smeary were gradually transformed into a crystalline suspension. After stirring over night at ca. 25eC, the suspension was cooled to 10eC and after ca. 1 hour was fi Itered by suction whilst excluding atmospheric moisture. Washed with 20 ml of tert.-butyl methyl ether. The moist filter cake was dried over night at ca. 30 mbar and at 30eC. A colourless, slightly hygroscopic crystal powder was obtained. There is no XRD diffractogram provided but 2: values with i ntensity are provided as below.
The above process as described is laborious and also not cost effective. Also as disclosed in the example 11 the crystalline valsartan disodium hydrate is hygroscopic and hence

might not be stable and shelf life would get affected. Thus there is a need to develop stable crystalline polymorphs of valsartan disodium, with the process involving be simple and cost-effective.
US Patent No. 8,877,938 B2 discloses Trisodium [3-((1S, 3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl -1 - butyl carbamoyl) propi onate-(S)-3 -methyl -2 -{pentanoyl{ 2 j-(tetrazol -5-y I ate) bi phenyl -4 -y I methyl} ami no)butyrate] hemipentahydrate in crystal line form.
EP Patent application no. 2340828 discloses the Trisodium [3-((1S, 3R)-1-biphenyl-4-
ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3-methyl-2->
(pentanoyl{2|-(tetrazol-5-ylate)biphenyl-4-yl methyl} amino)butyrate] in amorphous form
CN 105461647 application discloses sodium [3-((1S, 3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl -1 - butyl carbamoyl) propi onate-(S)-3 -methyl -2 -{pentanoyl{ 2 j-(tetrazol -5-y I ate) bi phenyl -4 -y I methyl} ami no)butyrate] in , § and .-amorphous form
PCT Publication No. WO 2007056546 A1 discloses amorphous sacubitril valsartan trisodium and various processes for preparation thereof.
T he above process as descri bed is laborious and also not cost effective. T hus there is a need to develop stable amorphous form of sacubitril valsartan trisodium, with the process involving be simple and cost-effective.
SUMMARY OF THE INVENTION
One aspect of the present invention is to provide a crystalline Form B1 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt and a process for the preparation thereof.
Second aspect of the present invention is to provide a process for preparation of crystal I ine Form B1 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt by dissolving N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt in

a suitable solvent; stirring at elevated temperature for a suitable time followed by cooling to an ambient temperature foil owed by isolation of crystalline Form B1 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4~amino-2R-methyl butanoic acid ethyl ester sodium salt
Third aspect of the present invention is to provide a crystalline Form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4~amino-2R-methyl butanoic acid ethyl ester sodium salt and a process for the preparation thereof.
Fourth aspect of the present invention relates to a process for preparation of crystalline Form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt by acidifying N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester calcium salt into free acidusingaq. HCI in a suitable solvent Reacting the N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester with a suitable base in a suitable solvent stirring at ambient temperature for a suitable time followed by cooling to an ambient temperature followed by isolation of crystalline Form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodi um salt
F i fth aspect of the present i nventi on i s to provi de processes for the preparati on of crystal I i ne Form B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt.
S i xth aspect of the present i nventi on rel ates to a process for preparati on of crystal I i ne F orm B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenyl phenyl methyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt by acidifying N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester calcium salt into free acidusingaq. HCI in a suitable solvent ReactingtheN-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester with a suitable base in a suitable solvent, stirring at ambient temperature for a suitable time followed by cooling to an ambient temperature foil owed by isolation of crystalline Form B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt

Seventh aspect of the present invention is to provide a crystalline Form B of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt
Eighth aspect of the present invention is to provide a crystalline Form B of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-A mine disodium salt fromamorphous(S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt
Ninth aspect of the present invention is to provide a crystalline Form B of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-M ethyl]-A mine disodium salt by dissolving amorphous(S)-N-(1 - Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine in a suitable solvent in presence of a suitable sodium source, stirring at an elevated temperature, removal of the solvent azeotropically followed by isolation of crystalline Form B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt
T enth aspect of the present i nventi on i s to provi de crystal I i ne Form P of (S)- N-( 1 -Carboxy-
2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-
Amine disodium salt from amorphous (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine using an aromatic hydrocarbon as the solvent.
Eleventh aspect of the present invention is to provide crystalline Form B of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-A mine disodium salt fromamorphous(S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine using a sodium source and a suitable solvent.
Twelfth aspect of the present invention relates to process for preparation of amorphous form of sacubitril valsartan trisodium by dissolving sacubitril valsartan trisodium in a suitable solvent.

Thirteenth aspect of the present invention relates to process for preparation of amorphous form of sacubitril valsartan trisodium by acidifying calcium salt of sacubitril to sacubitril free acid and treati ng with sodi urn hydroxi de and valsartan i n presence of a suitable solvent
Fourteenth aspect of the present invention relates to process for preparation of amorphous solid dispersion of sacubitril valsartan trisodium with an excipient by acidifying calcium salt of sacubitril to sacubitril free acid and treating with sodium hydroxide, excipient and valsartan in presence of a suitable solvent
The term "suitable solvent" used in the present invention is selected from, but not limited to "aliphatic hydrocarbon solvents" such as heptane, hexane, pentane, acetone, methyl ethyl ketone, methylisobutyI ketone, ethyl acetate, methyl acetate, isopropyl acetate, n-butyl acetate, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol and the like." poly hydroxy alkanes" such as ethylene glycol, propane 1,2 diol, propane 1,3 diol, butane 1,2 diol, butane 2,3 diol, aromatic hydrocarbon solvents such as toluene, benzene and the I ike.
The term "sodium source, used in the present invention is selected from, but not limited to sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium methoxide, sodium ethoxideandthelike.
The term "excipient, used in the present invention is selected from, but not limited to microcrystalline cellulose, hydroxypropyl methyl cellulose, silicon dioxide, hydroxypropyl cellulose, cellulose acetate, mannitol, sorbitol and the like.
BRIEF DESCRIPTION OF THE FIGURES
In order that the disclosure may be readily understood and put into practical effect, reference wi 11 now be made to exempl ary embodi ments as i 11 ustrated with reference to the accompanying figures. The figures together with a detailed description below, are incorporated in and form part of the specification, and serve to further illustrate the embodi ments and expl ai n vari ous pri nci pi es and advantages, i n accordance with the present disclosure wherein:

Figure 1 Illustrates the PXRD pattern of crystalline Form B1 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt
Figure 2: Illustrates the PXRD pattern of crystalline Form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt
Figure 3: Illustrates the PXRD pattern of crystalline Form B of N-(3-carboxyl-1-
> oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester
sodium salt
Figure 4: Illustrates the PX RD pattern of crystalline Form B of (S)-N-(1 -Carboxy-2-M ethyl- Prop- 1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt.
i Figure 5: Illustrates the IR pattern of crystalline Form B of (S)-N-(1 -Carboxy-2-M ethyl- Prop- 1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine di sodium salt.
Figure 6: Illustrates thePX RD of crystalline Form P of (S)-N-(1 -Carboxy-2-Methyl-
Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine
> di sodium salt.
Figure 7: Illustrates the PXRD pattern of amorphous form of Sacubitril valsartan trisodium complex.
T he method of analysi s of the compounds represented i n the f i gures as above are as bel ow:
PXRD analysis
About 300 nrg of powder sample was taken onto the sample holder and was tightly packed i on the sample holder uniformly by means of glass slide and PowderX-ray diffraction was recorded on BrukerD8 Advance diffractometer(Bruker-AXS, Karlsruhe, Germany) using Cu-K X-radiation (= = 1.5406 \ ) at40 kV and 30 mA powder.X-ray diffraction patterns were col I ected over the 2: :range 3"50e at a scan rate of 1 eVmi n.

DSC Analysis
DSC was performed on a Mettler Toledo DSC 822e module. 4-6 mg of sample was
pi aced i n cri mped but vented al umi ni um sampl e pans. T he temperature range was from
30-250 eC @ 10 eC/min. Samples were purged by a stream of nitrogen flowing at 80
mL/min.
IR Anlaysis
IR was performed on a Fisher Scientific (NICOLET-iS50-FTIR). About 5 nrg of sample was spread over the region of diamond ATR sampling station and collected the sample spectrum between 4000 cm-1 to 400 cm-1 to obtain a spectrum of suitable intensity (above 60 % transmission at 2000 cm-1).
DETAILED DESCRIPTION OF THE INVENTION
The term "suitable solvent" used in the present invention is selected from, but not limited to "ester solvents" such as ethyl acetate, methyl acetate, isopropyl acetate, n-butyl acetate and the like; "ether solvents" such as tetrahydrofuran, dimethyl ether, diethyl ether, diisopropyl ether, methyl tert-butyl ether (MT BE), 1,4-dioxane and the like; "hydrocarbon solvents" such as toluene, hexane, heptane, pet ether, xylene, cyclohexane and the like; "polar aprotic solvents" such as dimethyl acetamide, dimethylsulfoxide, dimethylformamide, N-methyl-2-pyrrolidone and the like; "ketone solvents" such as acetone, methylethyl ketone, methylisobutyI ketone and the Iike; "alcoholic solvents" such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol and the like; "chlorinated solvents" such as dichloromethane, chloroform, dichloroethane, carbon tetrachloride and the like; "nitrile solvents" such as acetonitrile, butyronitrile, isobutyronitrile and the like; "polar solvent" such as water or mixtures thereof; "aliphatic hydrocarbon solvents" such as heptane, hexane, pentane and the like; ; "aliphatic hydrocarbon solvents" such as acetone, methylethyl ketone, methyl isobuty I ketone, ethyl acetate, methyl acetate, isopropyl acetate, n-butyl acetate, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol and the like." poly hydroxy alkanes" such as ethylene glycol, propane 1,2 diol, propane 1,3 diol, butane 1,2 diol, butane 2,3 diol, aromatic hydrocarbon solvents such as toluene, benzene and the like.

The term "sodium source, used in the present invention is selected from, but not limited to sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium methoxide, sodium ethoxideandthelike.
The embodiments of the present invention are further described using specific examples herein after. The examples are provided for better understanding of certain embodiments of the invention and not; in any manner, to limit the scope thereof. Possible modifications and equivalents apparent to those skilled in the art using the teachings of the present description and the general art in the field of the invention shall also form the part of this specification and are intended to be included within the scope of it.
Example 1: Preparation of crystalline Form B1 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt.
AmorphousSacubitril sodium(1g) inmethyl isobutyl ketone (5 mL) was stirred for 10 mi n at 25-30 eC. The temperature of reaction mass was raised to 40-45 eC to get the clear solution. Stirred the reaction mass for 1 hr at 40-45 °C. During stirring, clear solution gradually transformed to crystalline suspension. The suspension was then cooled to 25-30 eC. T he suspensi on was sti rred at same temperature for 60 mi n. T he sol i d was col I ected by filtration and dried for 12 hrs at 30-35eC under vacuum to yield N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt as crystal line FormBI.
The PXRD pattern of Form B1 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenyl phenyl methyl )-4-ami no-2R -methyl butanoi c aci d ethyl ester sodi um salt i s shown i n figure 1.
IR (cm"1): 514.62, 603.40, 651.26, 695.70, 733.58, 760.93, 819.75, 850.60, 936.35, 1008.03,1025.23, 1085.23,1159.20, 1190.94,1265.08,1409.04, 1487.36,1562.78, 1646.99, 1721.91, 2936.16, 2977.43, 3336.91.
Example 2: Preparation of crystalline Form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt.

Sacubitril calcium (25 g.) in ethyl acetate was added 5 N HCI to adjust the pH to 1 to 1.5 and stirred for 10 to 20 minutes. T he reacti on mass was diI uted with water and Iayers were separated. The aqueous layer was extracted with ethyl acetate, organic layers were combined and concentrated to yield Sacubitril free acid. The concentrated mass of Sacubitril free acid, was added MEK (Methyl ethyl ketone) (3.0 vol.) and0.5N NaOH (0.9 eq). The reaction mass was stirred for 2 hrs at 25 °C. The reaction mass was concentrated and given acetonitrile strip off. MDC (3.0 vol.) and Toluene (6.0 vol.) were added to the residue and partially concentrated at 50°C to 5.0 vol. stage and then added n-Heptane (5.0 vol.). Stirred the obtained solid for 1 hour. Filtered and washed the solid with n-heptane. D ri ed the Sacubitri I sodi um under vacuum at 50 °C.
The PXRD pattern of Form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenyl phenyl methyl )-4-ami no-2R -methyl butanoi c aci d ethyl ester sodi um salt i s shown i n figure 2.
IR (cm1): 497.75, 552.98, 608.37, 651.29, 692.67, 732.22, 760.91, 812.97, 839.37, 872.29, 909.96, 933.29, 1015.49, 1099.64, 1128.13, 1162.15, 1189.91, 1242.81, 1270.88,1296.59, 1372.08,1416.31, 1434.94,1487.75,1523.64, 1564.18,1647.96, 1708.70, 1731.66, 2916.44, 2978.88, 3030.21, 3351.01.
Example3: Preparation of crystalline Form B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt.
Sacubitril sodium amorphous (1g) was added to n-heptane (50 mL) and stirred for 10 min at 25-30 eC. The reaction mass temperature was slowly raised to 90-95 eC and water was removed azeotropically. During azeotropic distillation, clear solution gradually transformed to crystalline suspension. The suspension was cooled to 25-30 °C. The suspension was stirred at same temperature for 15-30 min. The solid was collected by filtration and dried for 12 hrs at 30-35eC under vacuum to yield N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt as crystal line FormB.

Example4: Preparation of crystalline Form B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenyliriethyl)-4-amino-2R-nriethyl butanoic acid ethyl ester sodium salt.
Sacubitril calcium (1.0 Kg.) in ethyl acetate (7.0 Vol) was added 5 N HCI to adjust to pH 1 to 1.5 and stirred for 10 to 20 minutes. The reaction mass was diluted with water and aqueous I ayers were separated. T he aqueous I ayer was extracted wi th ethyl acetate, organi c layer were combined and concentrated to yield sacubitril free acid. The concentrated mass of sacubitri I free acid, was added n-heptane (10.0 V) and aq NaOH (0.9 eq.) and sti rred for 10 min at 25-30 eC. The reaction mass temperature was slowly raised to 90-95 eC and water was removed azeotropically. The clear solution gradually transformed to crystalline suspension. The suspension was cooled to 25-30 eC. The suspension was stirred at same temperature for 15-30 mi n. T he sol i d was col I ected by f i Itrati on and dri ed for 12 hrs at 30-35 eC under vacuum to yield 0.8 Kg of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt as crystal line form B.
The PXRD pattern of crystalline Form B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenyl phenyl methyl )-4-ami no-2R -methyl butanoi c aci d ethyl ester sodi um salt i s shown i n figure 3.
Example 5: Preparation of crystalline Form B of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt.
(S)-N-(1-Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt (3.0 g) was taken in to a RBF and MIBK (Methyl iso butyl ketone) (150 ml) was added. The temperature of reaction mass was slowly raised to reflux and water was removed azeotropically. During azeotropic distillation, the clear solution gradually transformed to crystalline suspension. The suspension thus formed was cooled to 85-90 °C. The suspension mass was stirred at same temperature for 15-30 min.

Filtered the reaction mass. The wet cake was dried for 10-12 hr at 30-35 °C under vacuum to yield crystalline FormB of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt (2.5 g).
Example 6: Preparation of crystalline Form B of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt.
To a solution of amorphous (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine(5.0g) in250ml MIBK (Methyl isobutyl ketone) was added 50 % aq. sodium hydroxide (0.96 g.) solution. The temperature of reaction mass was raised to reflux and water was removed azeotropically. During azeotropic distillation, clear solution gradually transformed to crystalline suspension. The suspension was cooled to 85-90 °C. The suspension mass was stirred at same temperature for 15-30 mi n. F i Itered the reacti on mass. T he wet cake was dri ed for 10-12 hr at 30-35 °C under vacuum to yield crystalline Form B of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt (4.48 g).
Example7: Preparation of crystalline Form B of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt.
To a solution of amorphous (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine(1.0 Kg) in MIBK (10 Vol.) (Methyl iso butyl ketone) was added 30 % Sodium Methoxide solution in methanol solution (0.88 Kg). The temperature of reaction mass was raised to reflux and methanol was removed azeotropi cal ly. T he suspensi on was mai ntai n under refI ux for around 2 hr. T he suspensi on was cool ed to around 25 to 30 °C. T he suspensi on mass was sti rred at same temperature for 15-30 min. Filtered the reaction mass. The wet cake was dried for 10-12 hr at 65 to 80 °C under vacuum to yield 0.88 Kg of crystal line FormB of (S)-N-(1 -C arboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt.

The PXRD pattern of Form B of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt is shown in figure 4.
IR (cm"1): 561.00, 669.42, 746.37, 760.47, 785.74, 814.68, 861.08, 942.02, 974.87, 1011.05,1101.83, 1137.16,1176.23, 1203.48,1265.48,1303.84, 1359.14,1405.62, 1459.74, 1507.88, 1618.07, 2871.76, 2931.82, 2960.36, 3406.61.
The IR pattern of crystalline Form B of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt is shown in figure 5.
Example 8: Preparation of crystalline Form P of (S)-N-(1 -Car boxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt.
To a solution of amorphous (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine(2.0g) in 100 ml toluene was added 50% aq. sodium hydroxide (0.38 g.) solution. The temperature of reaction mass was raised to refIux and water was removed azeotropically. During azeotropic distiNation, clear solution gradually transformed to crystalline suspension. The suspension was cooled to 85-90 °C. The suspension mass was stirred at same temperature for 15-30 min. Filtered the reaction mass. The wet cake was dried for 10-12 hr at 30-35 °C under vacuum to yield crystalline FormPof(S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt (1.81 g).
The PX R D pattern of Form P of (S)-N-(1 -Carboxy-2-Methyl-Prop-1-yl)-N-Pentanoyl-N-[2'-(1 H-Tetrazol-5-yl)-Biphenyl-4-yl-Methyl]-Amine disodium salt is shown in figure 6.
IR (cm-1): 561.01, 744.43, 760.41, 941.64, 975.11, 1013.32, 1105.33, 1135.85, 1175.04,1207.25, 1262.49,1361.28, 1404.28,1459.85,1507.61, 1629.05, 2871.74, 2959.93, 3420.93.

Example 9: Preparation of Amorphous Form of Sacubitril valsartan trisodium.
Trisodium Sacubitril valsartan (1.0 g.) was dissolved in a mixture of Heptane (50 ml) and Ethylene glycol (0.22 g.) mixture under reflux temperature. Removal of water from the reacti on mass was done by azeotropi c disti I lati on fol I owed by stri ppi ng off five ti mes with fresh Heptane. The suspension was cooled to 25-30 °C. The suspension mass was stirred at same temperature for 15-30 mi n. Fi Itered the reacti on mass. T he wet cake was dri ed for 10-12 hr at 30-35 °C under vacuum to yield Amorphous Form of Sacubitril valsartan trisodium Moisture Content 2.38%.
. Example 10: Preparation of Amorphous Form of Sacubitril valsartan trisodium.
Trisodium Sacubitril valsartan (1.0 g.) was dissolved in a mixture of Heptane (50 ml) and Ethylene glycol (0.11 g.) mixture under reflux temperature. Removal of water from the reacti on mass was done by azeotropi c disti I lati on fol I owed by stri ppi ng off five ti mes with fresh Heptane. The suspension was cooled to 25-30 °C. The suspension mass was stirred at same temperature for 15-30 mi n. Fi Itered the reacti on mass. T he wet cake was dri ed for 10-12 hr at 30-35 °C under vacuum to yield Amorphous Form of Sacubitril valsartan trisodium Moisture Content 1.35%.
Example 11: Preparation of Amorphous Form of Sacubitril valsartan trisodium.
Trisodium Sacubitril valsartan (1.0 g.) was dissolved in a mixture of Heptane (50 ml) and Propane 1,2 diol (0.27 g.) mixture under reflux temperature. Removal of water from the reacti on mass was done by azeotropi c disti I lati on fol I owed by stri ppi ng off five ti mes with fresh Heptane. The suspension was cooled to 25-30 °C. The suspension mass was stirred at same temperature for 15-30 mi n. Fi Itered the reacti on mass. T he wet cake was dri ed for 10-12 hr at 30-35 °C under vacuum to yield Amorphous Form of Sacubitril valsartan trisodium Moisture Content 2.48 %.
Example 12: Preparation of Amorphous Form of Sacubitril valsartan trisodium. Trisodium Sacubitril valsartan (1.0 g.) was dissolved in a mixture of Heptane (50 ml) and . Propane 1,2 diol (0.13 g.) mixture under reflux temperature. Removal of water from the

reacti on mass was done by azeotropi c di sti I lati on f ol I owed by stri ppi ng off five ti mes with fresh Heptane. The suspension was cooled to 25-30 °C. The suspension mass was stirred at same temperature for 15-30 mi n. Fi Itered the reacti on mass. T he wet cake was dri ed for 10-12 hr at 30-35 °C under vacuum to yield Amorphous Form of Sacubitril valsartan trisodium Moisture Content 2.46 %.
Example 13: Preparation of Amorphous Form of Sacubitril valsartan trisodium.
Trisodium Sacubitril valsartan (1.0 g.) was dissolved in a mixture of Heptane (50 ml) and Butane 2,3 diol (0.32 g.) mixture under reflux temperature. Removal of water from the reacti on mass was done by azeotropi c disti I lati on fol I owed by stri ppi ng off five ti mes with fresh Heptane. The suspension was cooled to 25-30 °C. The suspension mass was stirred at same temperature for 15-30 mi n. Fi Itered the reacti on mass. T he wet cake was dri ed for 10-12 hr at 30-35 °C under vacuum to yield Amorphous Form of Sacubitril valsartan trisodium Moisture Content 2.2 %.
Example 14: Preparation of Amorphous Form of Sacubitril valsartan trisodium.
Trisodium Sacubitril valsartan (1.0 g.) was dissolved in a mixture of Heptane (50 ml) and Butane 2,3 diol (0.16 g.) mixture under reflux temperature. Removal of water from the reacti on mass was done by azeotropi c disti I lati on fol I owed by stri ppi ng off five ti mes with fresh Heptane. The suspension was cooled to 25-30 °C. The suspension mass was stirred at same temperature for 15-30 mi n. Fi Itered the reacti on mass. T he wet cake was dri ed for 10-12 hr at 30-35 °C under vacuum to yield Amorphous Form of Sacubitril valsartan trisodium Moisture Content 1.8%.
Example 15: Preparation of Amorphous Form of Sacubitril valsartan trisodium.
To a solution of Sacubitril calcium (1.0 Kg) in ethyl acetate (7.0 L) added 2N HCI to neutralize at 15-20eC. Organic layer was washed with dil. HCI followed by water and brine solution. The organic layer was added with Valsartan (0.97 Kg), ethyl acetate and aq. Sodium hydroxide solution (0.64 Kg). Distilled off the ethyl acetate and reaction mass was stripped of with ethyl acetate thrice (2 L x3). The reaction mass was added with ethyl

acetate (5 L), heptane (25 L) and propanediol (0.053 Kg) to the reaction mass at 25-30eC. T he reacti on mass was heated to ref I ux. T he solvent i n the reaction mass was partial ly (15.0 Vol.) distilled off and reaction mass was stripped off with heptane thrice. Maintain the reacti on mass at ref I ux temperature for an hour. C ool the reacti on mass to 25-30eC. F i Itered off the product and washed the wet cake with heptane. The product was dried at 60eC to yield (1.69 Kg) of Amorphous Form of Sacubitril valsartan trisodium.
T he PX R D pattern of amorphous form of Sacubitri I valsartan trisodi um complex is shown in figure 7.
Example 16: Preparation of Amorphous solid dispersion of Trisodium Sacubitril valsartan with silicified micro crystalline cellulose
To a solution of Sacubitril calcium in ethyl acetate (7.0 vol) added 2N HCI (2.5 vol) to neutralize at 15-20 eC. Organic layer was washed with dil. HCI followed by water and brine solution. The organic layer was added with Valsartan, ethyl acetate (13 vol) andaq. Sodium hydroxide solution (3.0 eq) followed by silicified micro crystalline cellulose (100% w/w) to the reaction mass. Distil off the ethyl acetate and strip of with ethyl acetate trice in order to control the moisture. Add ethyl acetate (5vol), heptane (25vol) and propanediol (0.3eq) to the reacti on mass at 25-30 eC. H eat the reacti on mass to the ref I ux. R emove the solvent (15 vol) and add same amount of heptane trice in order to get rid of ethyl acetate and moisture. Maintain the reaction mass at reflux temperature for an hour. Cool the reaction mass to 25-30eC. Fi Iter the product under nitrogen atmosphere and wash the wet cake with heptane. Dry the product at 60eC.
Example 17: Preparation of Amorphous solid dispersion of Trisodium Sacubitril valsartan with mannitol
To a solution of Sacubitril calcium in ethyl acetate (7 vol) added 2N HCI (2.5 vol) to neutralize at 15-20 eC. Organic layer was washed with dil. HCI followed by water and brine solution. The organic layer was added with Valsartan, ethyl acetate (13 vol) andaq. Sodium hydroxide solution (3.0 eq) followed by mannitol (100% w/w) to the reaction mass. Distil off the ethyl acetate and strip of with ethyl acetate trice in order to control the moisture.

Add ethyl acetate (5vol), heptane (25vol) and propanediol (0.3eq) to the reaction mass at 25-30eC. Heat the reaction mass to the reflux. Remove the solvent (15vol) and add same amount of heptane trice in order to get rid of ethyl acetate and moisture. Maintain the reaction mass at reflux temperature for an hour. Cool the reaction mass to 25-30eC. Filter the product under nitrogen atmosphere and wash the wet cake with heptane. D ry the product at60eC.

CLAIMS
1. Crystalline form B1 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt characterized by an X-ray powder diffraction (X RPD) spectrum having peak reflections at about 3.7, 7.4, 11.8, 12.6,16.4, 16.6, 17.3,18.4,19.2,19.9, 20.7, 22.5 and 23.5e 0.2 degrees 2 theta.
2. A process for the preparation of crystalline form B1 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt; the process comprising:

a) Heating a solution of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt in a suitable solvent at elevated temperature;
b) C ool i ng the sol uti on;
c) Isolating the crystalline form B1 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt.

3. The process according to claim 2, wherein suitable solvent is selected from heptane, hexane, pentane, acetone, methyl ethyl ketone, methyl isobutyI ketone, ethyl acetate, methyl acetate, isopropyl acetate, n-butyl acetate, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol and the I ike.
4. Crystalline form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt characterized by an X-ray powder diff racti on (X R PD) spectrum havi ng peak ref lecti ons at about 3.2, 3.6,4.0, 6.4, 12.1,17.8, 18.5, 20.0, 21.0 and 21.7 e0.2 degrees 2 theta.
5. A process for the preparation of crystalline form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt; the process comprising:
a) Converting N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester calcium salt into N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester free acid in presence of a suitable acid and a suitable solvent at elevated temperature;

b) T reati ng N-(3-carboxyl -1 -oxopropyl)-(4S)-( p-phenyl phenyl methyl)-4-ami no-2R-methyI butanoi c aci d ethyl ester from step a) with a sodi um source;
c) Isolating the crystalline form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt.
6. A process for the preparation of crystalline form B of N-(3-carboxyl-1-oxopropyl)-
(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium
salt; the process comprising:
a) Converting N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester calcium salt into N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester free acid in presence of a suitable acid and a suitable solvent at elevated temperature;
b) T reati ng N-(3-carboxyl -1 -oxopropyl)-(4S)-( p-phenyl phenyl methyl)-4-ami no-2R-methy I butanoi c aci d ethyl ester from step a) with a sodi um source;
c) Heating the reaction mass and azeotropic removal of water from the reaction mixture;
d) Isolating the crystalline form B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt.

7. The process according to claim 6, wherein sodium source is selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium methoxide and sodium ethoxide.
8. Crystal line form B of (S)-N-(1 -carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1 H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-amine disodium salt characterized by an X-ray powder diffracti on (XRPD) spectrum having peak reflections at about 6.5, 8.4, 8.7, 9.6, 13.0,17.4, 19.6, 21.1, 23.9 and 26.1 e0.2 degrees 2 theta.
9. A process for the preparation of crystalline form B (S)-N-(1 -carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1 H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-amine disodium salt; the process comprising:

a) Treating a solution of (S)-N-(1 -carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1 H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-amine with a sodium source.
b) Heating the reaction mass and azeotropic removal of water from the reaction mixture.

c) Cooling the reaction mixture and isolating the crystalline Form B of (S)-N-(1 -carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1 H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-amine disodiurn salt
10. The process according to claim 9, wherein sodium source is selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium methoxide and sodium ethoxide.
11. Crystal line form P of (S)-N-(1 -carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1 H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-amine disodium salt characterized by an X-ray powder diffracti on (XRPD) spectrum having peak reflections at about 5.2, 5.6, 6.6, 7.3, 8.1,10.4, 11.2, 14.4,19.6and23.1 e0.2 degrees2theta.
12. A process for the preparation of crystalline form P (S)-N-(1 -carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1 H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-amine disodium salt; the process comprising:

a) Treating a solution of (S)-N-(1 -carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1 H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-amine with a sodium source;
b) Heating the reaction mass and azeotropic removal of water from the reaction mixture;
c) Cooling the reaction mixture and isolating the crystalline Form P of (S)-N-(1 -carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1 H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-amine disodium salt

13. The process according to claim 12, wherein sodium source is selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium methoxide and sodium ethoxide.
14. A process for the preparati on of amorphous form of tri sodi um salt of val sartan sacubitri I complex, the process comprising:

a) Converting N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester calcium salt into N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester free acid in presence of a suitable acid and a suitable solvent;
b) T reati ng N-(3-carboxyl -1 -oxopropyl)-(4S)-( p-phenyl phenyl methyl)-4-ami no-2R-methyl butanoic acid ethyl ester from step a) and (S)-N-(1 -Carboxy-2-Methyl-

Prop-1-yl)-N-pentanoyl-N-[2'-(1 H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-amine with a sodi um source i n presence of one or more suitable solvents;
c) H eati ng the reacti on mi xture to an el evated temperature;
d) C ool i ng the reacti on mass i sol ati ng of amorphous form of tri sodi um salt of val saltan sacubitril complex.

15. The process according to claim 14, wherein sodium source is selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium methoxide and sodium ethoxide.
16. The process according to claim 14, wherein suitable solvent is selected from heptane, hexane, pentane, acetone, methyl ethyl ketone, methyl isobutyI ketone, ethyl acetate, methyl acetate, isopropyl acetate, n-butyl acetate, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol and the like; "poly hydroxy alkanes" such as ethylene glycol, propane 1,2 diol, propane 1,3 diol, butane 1,2 diol, butane 2,3 diol; and aromatic hydrocarbon solvents such as tol uene, benzene and the I ike.
17. An amorphous solid dispersion of sacubitril-valsartan complex comprising amorphous sacubitril-val sartan complex and one or more excipient
18. The amorphous solid dispersion of sacubitril-valsartan complex of claim 17, wherein the excipient is selected from microcrystalline cellulose, hydroxy propyl cellulose, hydroxypropylmethyl cellulose, mannitol and sorbitol.
19. An amorphous solid dispersion of sacubitril-valsartan complex comprising amorphous sacubitril-valsartan complex and microcrystalline cellulose.
20. An amorphous solid dispersion of sacubitril-valsartan complex comprising amorphous sacubitril-valsartan complex and mannitol.